Safety and Efficacy of Mobic Inj. (Meloxicam) for the Patients With OA or RA: Observational Study

Completed

• Conditions: Osteoarthritis; Arthritis, Rheumatoid

• Registration Number: NCT00612885
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

The main objective of this PMS study was to monitor and assess the safety of Mobic® intramuscular injection (7.5mg \~ 15mg, q.d.) up to 3 days (in case of need for prolonged treatment, switch to Mobic® capsule therapy was possible) in Korean patients with osteoarthritis and rheumatoid arthritis.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-03
• Primary Completion: 2005-08
• Study Completion: 2005-08
• Study First Submitted: 2008-01-30
• Study First Submitted QC: 2008-02-11
• Study First Posted: 2008-02-12
• Status Verified: 2013-10
• Last Update Submitted: 2013-10-31
• Last Update Posted: 2013-11-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 425

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence of adverse events	up tp 3 day
Efficacy assessment by the treating physician	up to 3 day
Combined efficacy, safety and tolerability assessment by the treating physician	up tp 3 day

Trial Locations

Locations (1)

Boehringer Ingelheim Investigational Site; 🇰🇷 Seoul, Korea, Republic of